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INTRODUCTION
Clostridium difficile (C. difficile) is currently considered to be
one of the most formidable and prominent causes of nosocomial
infections. C. difficile -associated diarrhea (CDAD) might have
various symptoms from mild diarrhea to fulminant pseudomem-
branous colitis, toxic mega-colon, and sepsis. The main cause of
this condition is the overwhelming of the normal intestinal flora by
the dominant C. difficile via the antibiotic turmoil, followed by toxin
production by the bacteria. However, the challenge is not only the
complications which come after antibiotic exposure, but also the
challenges the condition poses to the prevention and control of
nosocomial transmission. This is due to the fact that C. difficile
spores can be shed into the hospital environment by individuals
who are infected or colonized. Therefore accurate diagnosis fol-
lowed by effective therapy in combination with early isolation of the
patients is of vital importance.
Various laboratory test are currently available for the detection
of C. difficile or its toxins (1). The most sensitive diagnostic method,
considered the gold standard method for the detection of toxi-
genic C. difficile, is the culturing of the organism under anaerobic
conditions with toxin testing of the isolated C. difficile. However, it
takes several days to get a result and is thus not suitable for the
early diagnosis of CDAD patients. Polymerase chain reaction
(PCR) testing has recently developed highly sensitive and specific
methods, however it is still costly and it is difficult to obtain quick
results at hospitals where gene amplification machines are not
equipped. Additionally, the high sensitivity of the PCR can result in a
high proportion of false positive results, as it cannot distinguish
CDAD patients from the patients with C. difficile asymptomatic car-
riage. Therefore, various enzyme immunoassay (EIA) based screen-
ing methods to detect C. difficile glutamate dehydrogenase (GDH)
and toxins A and B have been developed and are in widespread use
(2).
The C. Diff Quik Chek Complete assay is a rapid membrane EIA
assay that combines the detection of both GDH and the toxin A
and B (3). It has been widely use in hospitals due to its simplicity,
rapidity, and cost-effectiveness. Although the performance for the
detection for GDH and toxins had been improved compared with
other EIA kits (4), the sensitivity and specificity of GDH detec-
tion by this kit was reported to be 91.0

100% and 92.4

94.6%,
whereas those for toxin detection were 61.9

78.6% and 96.9

99.2%,
respectively (3, 5, 6). Because of the discrepancies in the sensitivity
between GDH and toxin detection, there is uncertainty regarding
clinical decision making for patients with a GDH positive/toxin
negative result using this kit. The GDH positive/toxin negative
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results could indicate the presence of toxin producing C. difficile or
toxin non

producing C. difficile, or the lack of C. difficile. We there-
fore evaluated GDH positive/toxin negative cases detected using
the C. Diff Quik Chek Complete assay and compared them to the
results obtained by conducting anaerobic cultures followed by
toxin detection.
MATERIALS AND METHODS
Study site, stool specimens and study eligibility criteria
The study was performed in the Tottori University Hospital, a
tertiary medical hospital with 40 departments with 697 beds,
which is located in the San- in district of West Japan. Liquid or semi-
solid stool samples obtained from patients hospitalized and submit-
ted for C. difficile testing from April 2012 to March 2017 were in-
cluded in the study. All samples were tested within 24 h of receipt
using the C. Diff Quik Chek Complete assay. Stool samples nega-
tive for GDH were not tested further, since the negative predictive
value of GDH negative samples ranges between 92.4

100% (5, 6).
Samples that tested GDH positive and toxin negative were subse-
quently analyzed using anaerobic cultures followed by toxin test-
ing of the isolated C. difficile. Additionally patients with a GDH
positive/toxin negative result were asked to submit another stool
sample for additional C. difficile culturing.
We registered the results of the first stool sample as one epi-
sode and excluded the result of subsequent tests. Additionally,
we excluded the samples from the patients who had been hospital-
ized for less than 2 days because a diagnosis of hospital -acquired
CDAD requires the occurrence of diarrhea at least 48 h after
admission.
This study was conducted in accordance with the Declaration of
Helsinki 1975, as revised in 2008 and was approved by the Tottori
University Hospital Research Ethics Board (No. 17A079). The re-
quirement for written informed consent was waived by the ethical
board.
C. Diff Quik Chek Complete assay and culture of C. difficile fol-
lowed by toxin testing
All samples were tested using the C. Diff Quik Chek Complete
assay (Alere Inc., Waltham, MA, USA) in accordance with the manu-
facturer’s instructions. For culture testing, flesh stool (1 mL) was in-
cubated with equal amounts of 99% ethanol (Wako Pure Chemical In-
dustries Ltd., Osaka, Japan) at room temperature for 30 min. Thereaf-
ter, 2 to 3 drops of liquid stool were inoculated onto cycloserine-
cefoxitin-mannitol agar (CCMA) EX (Nissui Pharmaceutical Co.
Ltd., Tokyo, Japan). Plates were incubated anaerobically for as
long as 3 days at 35 and the suspicious colonies were identified
using MALDI Biotyper (Bruker Corporation, Billerica, MA, USA).
Colonies identified as C. difficile were further tested for toxin
positivity using the C. Diff Quik Chek Complete assay.
Data collection
The gold standard for the diagnosis of toxigenic CDAD in this
study was the detection of C. difficile by culture followed by the
confirmation of toxin production. The patients with GDH positive
and toxin negative results using the C. Diff Quik Chek Complete
assay were grouped as toxigenic C. difficile positive and toxigenic
C. difficile negative according to the gold standard testing mecha-
nism. Clinical histories of the patients in each group were collected
from medical records. These included demographic characteris-
tics (age, gender) and clinical conditions [body mass index (BMI)],
nutritional status indicated by controlling nutritional status (CONUT)
score (7), length of hospitalization, antibiotic exposure, medical
treatment prior to the diagnosis of CDAD [insertion of nasogastric
tube, urgent admission to intensive care unit (ICU), admission of
surgical service], and laboratory test results [total white blood cells,
hemoglobin, albumin, blood urea nitrogen (BUN), creatinine, esti-
mated glomerular filtration rates (eGFR)].
Statistical analyses
To assess the relationship between clinical histories and the
presence of toxigenic C. difficile in the patients with GDH positive/
toxin negative results using the C. Diff Quik Chek Complete assay,
the groups were compared using univariate and multivariate analy-
ses. For univariate analysis, Student’s t - tests were used to compare
continuous variables and Mann-Whitney U tests were used to com-
pare scale or ordinal variables. Chi -squared tests were used to com-
pare proportions for categorical variables. For multivariate analy-
sis, multiple logistic regression analysis was performed. Statistical
analyses was performed using IBM SPSS Statistics version 25.0 for
Windows (IBM, Chicago, IL, USA) and P values of 0.05 were
considered statistically significant.
RESULTS
During the study period, a total of 2675 stool specimens were
submitted for C. difficile antigen testing. Specimens were first
tested using the C. Diff Quik Chek Complete assay. Of all speci-
mens, 234 (8.8%) were GDH positive/toxin positive (GDH+/
Toxin+), 356 (13.3%) were GDH positive/toxin negative (GDH+/
Toxin

), and 2085 (77.9%) were GDH negative/toxin negative
(GDH

/Toxin

). Of 356 GDH positive/toxin negative specimens,
136 were excluded from the analysis (11 outpatients and 125 did not
meet the study eligibility criteria) and remaining 220 specimens
were further analyzed by a C. difficile culture followed by toxin
testing. Of 220 cultured specimens, toxigenic C. difficile and non-
toxigenic C. difficile were identified in 139 (63.2%) and 60 (27.3%)
samples, respectively, while C. difficile were not identified in 21
(9.6%) samples (Figure 1). The positive predictive value (PPV) of
GDH positive/toxin negative test results for CDAD was 63.2%.
We next compared the clinical histories of the toxigenic C. difficile
positive (139 patients) and negative (81 patients) patients. The
toxigenic C. difficile -negative patients were the combined group of
nontoxigenic C. difficile -positive (60 patients) and culture-negative
(21 patients) patients. The demographic characteristics, clinical
conditions and laboratory test results of the two groups were
Figure 1. Study enrollment and the testing results
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shown in Table 1. The demographic characteristics did not signifi-
cantly differ between the groups. However, patients with toxigenic
C. difficile had significantly lower BMI compared to those without
toxigenic C. difficile (19.50.4 vs. 20.90.5, P = 0.02).
We further investigated the risk factors of toxigenic C. difficile
detection in the patients with GDH positive/toxin negative results
using the C. Diff Quik Chek Complete assay by conducting multi-
variate logistic regression analysis. As P -values of BMI, WBC
count and eGFR were0.2 upon univariate analysis, they were
included as risk factors in the multivariate analysis. Only lower
BMI was a significant risk factor for toxigenic C. difficile identifica-
tion in this patient group [odds ratio (OR) 0.894, 95% confidence
interval (CI) 0.8280.966, P = 0.01] (Table 2).
DISCUSSION
Rapid membrane EIA methods to detect C. difficile antigens and
toxins are now widely used in clinical settings. Among them, C. Diff
Quik Chek Complete assay is one of the most commonly used
assay kits, due to its improved sensitivity and specificity. This kit
combines the detection of both GDH and toxins A and B, but a
discrepancy exists between the sensitivities for detecting GDH and
the toxins ; the sensitivity for GDH detection is higher than that for
the toxins. As a result, conflicting GDH positive/toxin negative
results can be obtained using this kit stemming from three possible
causes. One is the presence of toxigenic C. difficile, although the
toxin cannot be detected due to the lower detection sensitivity for
the toxin. The second is the existence of nontoxigenic C. difficile, as
detected by the kit. The third possibility is the absence of C. difficile,
with GDH being falsely detected. In this study, we investigated the
results of C. Diff Quik Chek Complete assay in our hospital over a
five year period, and revealed that 13.3% of the population investi-
gated had GDH positive/toxin negative results. Among them,
63.2% of the samples were toxigenic C. difficile positive based on the
confirmatory culture results followed by toxin testing. These data
suggest that there is a large number of patients with GDH positive/
toxin negative results based on the C. Diff Quik Chek Complete
assay who are likely true CDAD patients. Additionally, our uni-
variate and multivariate analysis revealed that lower BMI was a risk
factor for toxigenic CDAD in the patients with GDH positive/toxin
negative results.
The possibility of infection with toxigenic C. difficile varies sig-
nificantly from study to study. Based on a PubMed search, various
data have been reported regarding the PPV of the C. Diff Quik
Chek Complete assay for the detection of toxigenic C. difficile
among patients with GDH positive/toxin negative results (Table
3). The PPV reported in our study (63.2%) was relatively high com-
pared to the range reported in previous studies (21.794.7%).
PPV is strongly influenced by the prevalence of toxigenic C. difficile
among the study patients. Therefore, most of the samples in our
study might have been obtained exclusively from patients with
high probabilities of CDAD, such as those who had liquid or semi-
solid stools during antibiotic therapy.
Our findings provide theoretical evidence to initiate isolation
precautions and specific therapy for the patients with GDH positive/
toxin negative results before confirmatory test results are ob-
tained. Although such strategies are generally recommended
Table 1. Clinical backgrounds of the toxigenic C. difficile positive and negative patients
variable
Toxigenic C.
difficile positive
n=139
Toxigenic C.
difficile negative
(toxin/culture negative)
n=81
P -value statistics
Demographic characteristics
Age, mean yearsSD 69.21.5 67.12.4 0.43 *
Sex, no. of patients (Male / Female) (83 / 56) (52 / 29) 0.51 †
Clinical conditions
BMI (kg/m2), meanSD 19.50.4 20.90.5 0.02 *
CONUT score, median (IQR) 2.5 (23) 2 (13) 0.42 ‡
Length of hospitalization, mean daysSD 34.04.5 31.14.3 0.71 *
Antibiotic exposure, no. (%) of patients 75 (54.0) 47 (58.0) 0.56 †
Medical treatment prior to CDAD, no. (%) of patients
Nasogastric - tube use 20 (14.4) 16 (19.8) 0.35 †
Urgent admission 10 (7.2) 7 (8.6) 0.70 †
Admitted surgical service 34 (24.5) 19 (23.5) 0.87 †
Laboratory test results, meanSD
Total WBC count (×103/μL) 9.330.57 7.840.52 0.08 *
Total lymphocytes count (/mm3) 107178 1134117 0.64 *
Hemoglobin (g/dL) 10.10.2 9.90.2 0.39 *
Albumin (g/dL) 2.70.1 2.60.1 0.80 *
BUN (mg/dL) 26.22.2 24.31.9 0.53 *
Creatinine (mg/dL) 1.50.2 1.60.3 0.58 *
eGFR (mL/min/1.73m2) 89.510.1 70.28.7 0.20 *
*Student’s t - test, †Chi -squared test, ‡Mann-Whitney U test.
Data are number, median (IQR, interquartile range) or meanSD.
CONUT score, controlling nutritional status score (7) : the automatic assessment of nutritional status based on 3 serum parameters : albumin,
hemoglobin and total lymphocyte count. Nutritional status was classifies as follows : normal, 01 ; light, 24 ; moderate, 58 ; sever, 912.
BMI, body mass index ; BUN, blood urea nitrogen ; eGFR, estimated glomerular filtration rate.
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(8), it is difficult to implement these practices without definitive
evidence of these recommendations, as the isolation precautions
for CDAD patients are costly and are resource intensive for hospi-
tals (i.e. require isolation-rooms). Therefore, similar investiga-
tions in every hospital are of vital importance.
In this study we additionally found that low BMI was a possible
risk factor for the development of toxigenic CDAD among those
with GDH positive/toxin negative results using the C. Diff Quik
Chek Complete assay. To our knowledge this is the first study to
investigate risk factors in this patient population. There is limited
information in the literature on BMI of patients who harbor toxi-
genic C. difficile. One study reported a CDAD case that was suc-
cessfully treated with fecal microbiota transplantation and showed
weight gain after receiving stools (9). Another study indicated that
low BMI is related to impaired immune function (10), and immuno-
suppression is one of the risk factors of CDAD (11). Therefore, the
observed association between lower BMI and toxigenic C. difficile
in the present study may be mediated by factors that influence
the microbiome, or impaired immunological functions of patients
with low BMI. Future studies are warranted to identify the factors
responsible for the association between low BMI and existence of
toxigenic C. difficile.
It has been previously reported that antibiotic use (12), advanced
age, hospitalization, severe illness, gastric acid suppression, feed-
ing tubes, gastrointestinal surgery, and cancer chemotherapy are
risk factors for CDAD (11, 13-16). Our results differed from those
from previous studies ; previous antibiotic use which is the most
common risk factor for CDAD was not identified in our study.
This is due to the fact that we focused on patients with GDH
positive/toxin negative results based on the C. Diff Quik Chek
Complete assay in this study rather than the general patient popula-
tion. Most of our study patients possibly had already been pre-
scribed antibiotics, because CDAD was suspected when the stool
samples were collected. For the same reason, previously reported
risk factors for CDAD in the general population might be not be
identified as risk factors in specific subgroups of patients.
Our study was limited by the fact that it was a retrospective study
performed in a single tertiary hospital. However, to our knowledge,
this was the second largest study to have ever investigated this
topic (Table 3). Additionally, as this was a retrospective study, fu-
ture prospective studies are needed to confirm our findings.
In conclusion, a substantial proportion of the patients with GDH
positive/toxin negative results using the C. Diff Quik Chek Com-
plete assay are infected with toxigenic C. difficile and are therefore
considered to have true CDAD. This was the case if the specimens
were taken from adequate patients such as patients with liquid or
semisolid stool after antibiotic use. Investigation of such patients in
each hospital provides the theoretical background for the imple-
mentation of isolation and therapy strategies for these individuals.
Low BMI is an additional risk factor which can be used to identify
the patients with true CDAD in this patient population. These data
will helpful to adopt pragmatic strategies for the management of
these patients before confirmatory test results are available in each
hospital.
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Table 2. Odds ratios for toxigenic C. difficile existence according to
various patients’ characteristics
variable Odds ratio 95% Confidenceinterval P -value
BMI (kg/m2) 0.894 0.828

0.966 0.01
Total WBC count 1.039 0.981

1.100 0.20
eGFR (mL/min/1.73 m2) 1.002 0.996

1.007 0.52
Table 3. Summary of articles reporting the prevalence of toxigenic C. difficile existence among the GDH positive/toxin negative samples
judged by C. Diff Quik Check Complete assay
Author Year Country Reference methods Number of Samplestested by the assay
Number of GDH
positive/toxin
negative (%)
Number of
Toxigenic C. difficile
detected (%*)
Quinn CD et al. (17) 2010 USA PCR 174 23 (13.2) 5 (21.7)
Sharp SE et al. (18) 2010 USA PCR and culture 284 27 (9.5) 15 (55.5)
Swindells J et al. (19) 2010 UK PCR and culture 150 11 (7.3) 8 (72.7)
Kawada M et al. (6) 2011 Japan Culture 60 9 (15) 6 (66.6)
Orellana-Miguel MA et al. (20) 2012 Spain Culture 970 60 (6.18) 25 (41.7)
Culbreath K et al. (21) 2012 USA PCR 4321 566 (13.1) 342 (60.4)
Vasoo S et al. (22) 2014 USA PCR 192 25 (13.02) 10 (40)
Alcala L et al. (23) 2015 Spain PCR and culture 979 103 (10.5) 49 (47.5)
Johansson K et al. (24) 2016 Sweden PCR and culture 419 36 (8.59) 17 (47.2)
Seo JY et al. (25) 2016 Korea PCR and culture 191 19 (9.9) 18 (94.7)
Collins DA et al. (26) 2017 Indonesia Culture 340 54 (15.0) 21 (38.9)
Kosai K et al. (27) 2017 Japan PCR and culture 118 36 (30.5) 19 (52.7)
This study 2017 Japan Culture 2675 356 (13.3) 139 (63.2)
*The percentages were the frequency of toxigenic C. difficile existence among the samples with GDH positive/toxin negative judged by C. Diff Quik
Check Complete assay.
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unit ; BUN, blood urea nitrogen ; eGFR, estimated glomerular filtra-
tion rates ; SD, standard deviation ; PPV, positive predictive value
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